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Retinoblastoma (Rb) gene is a tumour suppressor gene that
encodes the Rb family of proteins, which have an important role in
regulating cell cycle progression (Lee et al, 1987, 1988; Bookstein
et al, 1990; Wiman, 1993). Rb proteins have multiple phosphoryl-
ation sites as well as motif sequences for binding specific regula-
tory proteins. Phosphorylation of Rb proteins favours cell cycle
progression and cell proliferation (Wiman, 1993). During prolifer-
ation, Rb protein phosphorylation increases in the late G1 phase of
the cell cycle, remains high in S and G2 phases, and then dephos-
phorylates during mitosis. Rb proteins have broad transcriptional
effects such as inhibiting E2F factor required for expression of
genes involved in DNA replication (Heskcth, 1997). Mutation or
deletion of the Rb gene can result in uncontrolled cell proliferation
(Lee et al, 1988; Bookstein et al, 1990; Heskcth, 1997). Rb
proteins interact with a variety of proteins, some of which have
been well characterized: E2Fq, ATF-2, p34CDC2, insulin, lamins,
PU.1 and retinoblastoma binding protein (RBP) (Defeo Jones et al,
1991; Huang et al, 1991; Kaelin et al, 1991, 1992; Heskcth, 1997).
Recently, a human IgG antibody that reacts with breast cancer
cells was found to be specific to the heptameric peptide sequence
KASIFLK within RBP-1 (Cao et al, 1999). Breast cancer patients
had high titres of anti-RBP-1 IgG antibodies. Although the RBP
family comprises RBP-1 and RBP-2, only the former expresses
KASIFLK (Fattaey et al, 1993; Otterson et al, 1993). To our
knowledge, this peptide sequence is not present in any other
human protein sequence. The functions of RBP-1 and RBP-2
remain unknown (Fattaey et al, 1993; Otterson et al, 1993;
Heskcth, 1997).
Peptides recognized by antibodies are usually shorter than eight
amino acids, whereas peptides recognized by HLA class I
restricted T-cells are 9–12 amino acids in length. Previously, we
showed that peptide sequences recognized by human monoclonal
antibodies can also be recognized by human T-cells and that
the sequences are immunogenic in humans (Morioka et al, 1994;
Takahashi et al, 1997a, 1997b). In the present study we hypothe-
sized that a peptide sequence recognized by an antibody also
might be recognized by cytotoxic T lymphocytes (CTL) if adja-
cent amino acids with HLA class I motifs were added to the anti-
body-recognized sequence. To test this hypothesis we synthesized
decameric and nonameric RBP-1 peptides that contained
KASIFLK plus adjacent amino acids with known HLA-A2
and/or HLA-A3 anchor motif residues. Three such peptides –
GLQKASIFLK (247–256), KASIFLKTRV (250–259) and KASI-
FLKTR (250–258) – were used to stimulate peripheral blood
mononuclear cells (PBMC) from human donors with HLA-A2
and/or HLA-A3 phenotype. CTL lines established by stimulation
with RBP-1a and RBP-1b showed strong cytotoxic activity against
HLA-A2 and/or HLA-A3 matched peptide-pulsed B lympho-
blastoid cells (BLC) and against HLA-A matched established
breast cancer lines. The antigenic peptide sequence expressed by
RBP-1 may have potential clinical utility as a breast cancer
vaccine.
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SummaryRetinoblastoma binding protein 1 (RBP-1) is a 143-kDa nuclear phosphoprotein that promotes cell growth by inhibiting the product
of retinoblastoma tumour suppressor gene (pRB). We recently found that RBP-1 contains KASIFLK, a heptameric peptide (250–256)
recognized by human antibodies and overexpressed by breast cancer cells. In the present study, we demonstrate that human T-cells
stimulated with RBP-1 decameric peptides containing KASIFLK can kill human breast cancer cells. These decamers, GLQKASIFLK
(247–256) and KASIFLKTRV (250–259), have anchor motifs for both HLA-A2 and HLA-A3. Peripheral blood lymphocytes from 41 normal
donors were stimulated by these peptides in culture media containing 15IU ml–1 interleukin-2, 25IU ml–1 interleukin-7 and 500IU ml–1
granulocyte–macrophage colony-stimulating factor. Cytotoxic activity of the T-cells was assessed against autologous B lymphoblastoid cells
pulsed with each peptide. Stimulation by GLQKASIFLK generated specific cytotoxic T lymphocyte (CTL) lines from HLA-A2, A3 donors, HLA-
A2 donors and HLA-A3 donors. Stimulation with KASIFLKTRV generated specific CTL lines from HLA-A2 donors. No HLA-A2–, A3– CTL line
showed specific cytotoxicity against these target cells. These CTL lines were also cytotoxic against HLA-A2 and HLA-A3 breast cancer cells
but not against normal fibroblastoid cell lines, normal epidermal cell lines, or a melanoma cell line. RBP-1 peptide antigens may be of clinical
significance as a potential peptide vaccine against human breast cancer.
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Synthetic peptides
Two decapeptides and one nonapeptide of RBP-1 were synthe-
sized with a free COOH and NH2 terminal at Research Genetics,
Inc. (Huntsville, AL, USA). KASIFLKTRV and KASIFLKTR
were easily dissolved in standard culture medium; GLQKASIFLK
was insoluble in standard medium and therefore was dissolved in
100% dimethyl sulphoxide (DMSO) at 100 mg ml–1 and stored at
–20°C. Prior to use, all three peptides were diluted to 100 mg ml–1
in a culture medium and stored at 4°C for no more than 2 weeks.
Cell line establishment
Eleven breast cancer primary cultures were established from
metastases of individual patients as follows: surgical specimens
were minced and treated with RPMI-1640 containing 0.02%
trypsin, 200 U ml–1 of DNAase I and 0.15 g ml–1 of collagenase
(Sigma, St Louis, MO, USA) for 2 h at 37°C to make a single-cell
suspension. Cells were seeded to 12-well culture plates and
cultured in RPMI-1640 supplemented with 10% heat-inactivated
fetal calf serum (FCS) (Gemini Bioproducts, Calabasas, CA,
USA) plus penicillin G, streptomycin and amphotericin B (Gibco-
BRL, Grand Island, NY, USA). Non-adherent cells were removed
2 days later. A homogeneous cancer cell population was selec-
tively developed by cloning and passaging. These cells were
maintained in the above medium supplemented with insulin and
transferrin. JWCI-BA, a long-term (> 30 passages) breast cancer
cell line that expressed the breast cancer-associated KASIFLK
antigen was HLA-A2, A3, which was maintained in the same
culture medium was used in certain experiments. Fibroblastoid
and epidermoid primary cultures representative of normal cell
controls were established as previously described. Epidermal cells
were obtained by scraping a thin layer of epidermis, which was
separated from dermis by culturing overnight with RPMI-1640
containing 0.3% trypsin. JWCI-MA, which is a KASIFLK-nega-
tive, HLA-A2, A3 melanoma cell line (> 20 passages), was also
used as a control. All cell lines were subjected to immunohisto-
chemical analysis using a human anti-KASIFLK IgG antibody. All
control cell lines were proven to be negative for the KASIFLK
antigen, and all breast cancer cell lines were positive for the
antigen. Viral-transformed BLC lines were established from
normal donors by incubating PBMC with Epstein–Barr virus
(EBV) obtained from supernatant of B95-8 marmoset BLC line
(Morioka et al, 1994). HLA typing of all cell lines was carried out
by HLA antibody microcytotoxicity assay (Dr Paul Terasaki’s
laboratory at the UCLA School of Medicine) and/or by DNA poly-
merase chain reaction (PCR) assay. These assays tested peripheral
blood lymphocytes from donors of the cell lines.
Generation of CTL lines
PBMC were obtained from fresh blood of 41 normal healthy donors
by fractionation with Ficoll Hypaque gradient (Pharmacia Biotech,
Alameda, CA, USA). PBMC (3 ´ 106 per well) were cultured in a
24-well culture plate with AIM-V media (Gibco- BRL) containing
10% human AB heat-inactivated serum (Gemini Bioproducts) and
10 mg ml–1 of synthetic peptide. After 2 days, half of the culture
medium was replaced with fresh medium supplemented with 15 IU
ml–1 (final concentration) of interleukin-2 (IL-2) (R&D Systems,
Minneapolis, MN, USA) and 25 IU ml–1 of interleukin-7 (IL-7)
(R&D Systems). PBMC were transferred to new wells to remove
adherent cells. This procedure was repeated every 2 days to
completely remove adherent cells before the next peptide stimula-
tion. After 6 days, 3 ´ 106 of cryopreserved autologous PBMC were
thawed and incubated for 6 h with culture medium containing 500
IU ml–1 of granulocyte–macrophage colony-stimulating factor
(GM-CSF) (R&D Systems) and 10 mg ml–1 of the peptide. PBMC
were then irradiated at 5000 rads and non-adherent cells were
removed and used as feeder cells. Responder cells were added to
these adherent cells and then cultured. Two days later, half of the
medium was replaced with fresh medium containing IL-2 and IL-7,
and the responder cells were transferred to new wells. The same
procedure was repeated. At day 30, all responder cells were tested
for cytotoxicity against autologous EBV-transformed BLC pulsed
with peptide. Successful peptide-specific CTL lines were main-
tained for more than 16 weeks by restimulation with peptide and
cytokines every 6th day.
51Cr-release cytotoxic assay
51Cr-release cytotoxic assay was performed as previously described
(Morioka et al, 1994). Target cells were labelled with 100 mCi of
Na2
51CrO4 (Amersham, Arlington Heights, IL, USA). BLC targets
were prepulsed with 10 mg ml–1 of the peptide for 2 h at 37°C before
effector cells were added. The percentage of specific lysis was
calculated as follows: 100 ´ [(experimental release2spontaneous
release)/(maximum release2spontaneous release)]. Spontaneous
release was determined by incubating target cells with medium only,
and maximum release was determined with 3% Triton X-100.
Spontaneous release and maximum release were counted in BLC
targets with and without peptide; no differences were observed. All
values were the average from triplicate samples.
Monoclonal antibody blocking
An antibody blocking assay was performed to assess CTL speci-
ficity. 51Cr-labelled target cells were incubated at 37°C with IgG
murine monoclonal antibody (mAb) against HLA class 1, HLA-
DR, and HLA-DQ (AMAC, Inc., Westbrook, ME, USA); HLA-A2
(clone BB7.2 ATCC); or HLA-A3 (clone GAP A3 ATCC). After
30 min, effector cells were added, and 51Cr-release CTL assay was
performed as described above.
Cold target inhibition assays
Effector cells were incubated with unlabelled cold targets (fibro-
blasts, PBMC, K562 cells and JWCI-BA breast cancer cell line) at
specific ratios in 96-well round-bottom microtitre plates for 1 h at
37°C. 51Cr-labelled hot targets were then added to the wells and
incubated at 37°C for 4 h. The E:T ratio was constant at 40:1.
RESULTS
HLA-A2 or HLA-A3 restricted recognition of RBP-1
peptide by CTL
The peptide sequences selected in this study – GLQKASIFLK,
KASIFLKTRV, and KASIFLKTR – were derived from the natural
RBP-1 protein sequences 247–256, 250–259 and 250–258, respec-
tively, and contain HLA-A2 and/or HLA-A3 motifs adjacent to the
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N- and/or C-terminal of the antibody-recognizing heptameric
sequence KASIFLK. GLQKASIFLK has anchor motifs for both
HLA-A2 and HLA-A3. K at position 10, L at position 9 and L at
position 2 are preferred anchor residues of HLA-A2. L at position
2 and K at position 10 are preferred anchor residues of HLA-A3.
KASIFLKTRV also has anchor motifs for HLA-A2 and HLA-A3:
A at position 2 and V at position 10 for HLA-A2, and A at position
2 and R at position 9 for HLA-A3. KASIFLKTR has a motif for
HLA-A3 only: A at position 2 and R at position 9. PBMC from 41
normal healthy donors were stimulated with these peptides: 15
expressed HLA-A2, 10 expressed HLA-A3, four expressed HLA-
A2 and HLA-A3 and 12 did not express HLA-A2 or HLA-A3 but
did express other HLA-A motifs. These binding motifs were based
on several published references (Celis et al, 1994a; Kawakami et
al, 1994; Rammensee et al, 1995; Rivoltini et al, 1995; Sidney et
al, 1996).
The cytotoxicity of each peptide-specific cell line was assessed
using autologous BLC pulsed with the respective peptide.
Stimulation by GLQKASIFLK, which has motifs for both HLA-
A2 and HLA-A3, generated strong CTL from HLA-A2 donors and
relatively weaker CTL from HLA-A3 donors. Cytotoxicity was
greater than 20% for CTL generated from four of four HLA-A2,
A3 donors, 11 of 15 HLA-A2 donors, and five of ten HLA-A3
donors. None of the CTL generated from 16 donors with other
HLA types (HLA-A2–, A3–) showed specific cytotoxicity greater
than 10%. These findings suggest that the recognition
of GLQKASIFLK by CTL is restricted by both HLA-A2 and
HLA-A3.
Table 1 HLA-restricted recognition of RBP-1 peptides by CTL derived from 12 normal donors
PBMC HLA-A Autologous BLC pulsed with:
donorsa type
GLQKASIFLKb KASIFLKTRV KASIFLKTR
+– + – + –
1 1, 1 3.7 ± 0.3c 3.3 ± 0.3 1.4 ± 0.1 0.9 ± 0.1 3.5 ± 0.3 3.8 ± 0.3
2 1, 2 42.7 ± 1.8 2.9 ± 0.3 26.6 ± 1.4 4.1 ± 0.4 0.0 ± 0.1 0.0 ± 0.2
3 1, 3 30.8 ± 1.4 3.1 ± 0.3 6.7 ± 0.5 7.2 ± 0.4 2.2 ± 0.2 2.1 ± 0.1
4 1, 24 5.4 ± 0.2 6.0 ± 0.4 3.5 ± 0.3 3.2 ± 0.3 4.4 ± 0.4 4.6 ± 0.3
5 2, 2 48.5 ± 1.9 5.1 ± 0.3 29.4 ± 0.9 8.9 ± 0.6 0.6 ± 0.2 1.5 ± 0.1
6 2, 3 58.9 ± 1.8 3.8 ± 0.3 35.1 ± 1.4 3.8 ± 0.2 5.3 ± 0.5 4.6 ± 0.3
7 2, 32 53.6 ± 21.5 7.2 ± 0.5 17.6 ± 0.9 2.4 ± 0.2 3.9 ± 0.3 3.3 ± 0.3
8 3, 11 29.3 ± 1.0 1.8 ± 0.2 13.7 ± 0.9 2.5 ± 0.2 11.8 ± 0.7 2.4 ± 0.3
9 3, 31 37.4 ± 1.0 6.5 ± 0.5 3.2 ± 0.3 3.6 ± 0.3 1.4 ± 0.2 2.0 ± 0.3
10 3, 68 24.2 ± 1.4 4.7 ± 0.2 0.8 ± 0.1 0.3 ± 0.1 4.2 ± 0.3 2.6 ± 0.2
11 25, 33 1.1 ± 0.2 1.9 ± 0.2 4.2 ± 0.4 3.8 ± 0.2 3.1 ± 0.3 2.5 ± 0.2
12 29, 30 4.3 ± 0.3 3.5 ± 0.3 2.9 ± 0.2 3.4 ± 0.3 1.7 ± 0.1 1.1 ± 0.2
aPBMC from normal donors were stimulated for 4 weeks with each of the three RBP-1 peptides and tested for their cytotoxicity using 51Cr-release assay. bTarget
cells were autologous EBV-transformed BCL with and without each peptide. cData are expressed as average per cent specific cytotoxicity and standard
deviation of two independent cytotoxicity assays at an E:T ratio of 40:1. Bold-face type indicates significant cytotoxicity of targets when peptide-pulsed.
Table 2 Cytotoxicity of peptide-specific CTL lines against cultured HLA-A2 and/or HLA-A3 breast cancer cells
Target cell line
(HLA-A type)a CTL lines against GLQKASIFLKc CTL lines against KASIFLKTRV
Donor numberd: 5 6 7 13 14 6 15 8 16
HLA-A: 2, 2 2, 3 2, 32 3, – 3, 31 2, 3 2, – 3, 11 3, 24
BA (2+, 3–)b 64.6 ± 1.9e 73.4 ± 2.1 52.8 ± 1.8 28.1 ± 1.5 42.7 ± 1.4 31.5 ± 1.3 23.2 ± 0.8 2.8 ± 0.4 10.2 ± 0.7
BB (2+, 3–)b 43.9 ± 1.3 45.4 ± 1.6 40.6 ± 1.6 2.2 ± 0.3 4.4 ± 0.4 16.1 ± 1.2 18.6 ± 1.3 2.1 ± 0.3 5.7 ± 0.5
BC (2+,3–)b 67.7 ± 2.1 63.3 ± 1.9 47.7 ± 1.4 4.5 ± 0.3 6.1 ± 0.4 36.7 ± 1.5 19.3 ± 1.1 4.0 ± 0.3 6.9 ± 0.4
BD (2+, 3–)b 20.2 ± 1.3 21.2 ± 1.5 18.2 ± 0.8 3.1 ± 0.4 4.7 ± 0.3 15.8 ± 1.1 13.5 ± 0.8 1.8 ± 0.2 5.3 ± 0.5
BE (2+, 3–)b 49.5 ± 1.6 47.8 ± 1.3 45.3 ± 1.5 3.4 ± 0.2 3.2 ± 0.3 21.4 ± 0.9 18.3 ± 1.4 3.4 ± 0.2 4.0 ± 0.3
BF (2–, 3+)b 6.1 ± 0.4 34.1 ± 1.4 8.5 ± 0.8 22.0 ± 1.1 33.4 ± 1.2 8.2 ± 0.6 4.9 ± 0.4 13.1 ± 1.0 10.8 ± 0.7
BG (2–, 3+)b 4.8 ± 0.4 22.1 ± 1.0 5.8 ± 0.3 18.5 ± 1.0 24.8 ± 1.2 4.6 ± 0.3 2.2 ± 0.2 3.3 ± 0.4 4.1 ± 0.3
BH (2–, 3–)b 2.6 ± 0.3 3.9 ± 0.3 4.6 ± 0.4 2.3 ± 0.2 2.9 ± 0.4 2.4 ± 0.4 2.7 ± 0.3 1.4 ± 0.1 4.8 ± 0.4
BI (2–, 3–)b 7.7 ± 0.5 5.8 ± 0.3 6.2 ± 0.6 3.5 ± 0.4 7.0 ± 0.5 5.1 ± 0.6 4.5 ± 0.5 2.6 ± 0.3 6.6 ± 0.3
BJ (2–, 3–)b 4.0 ± 0.2 3.3 ± 0.3 7.9 ± 0.6 4.2 ± 0.4 6.4 ± 0.4 3.9 ± 0.3 2.5 ± 0.2 2.0 ± 0.3 3.5 ± 0.3
BK (2–, 3–)b 5.5 ± 0.5 6.3 ± 0.3 5.6 ± 0.4 2.6 ± 0.3 4.3 ± 0.4 5.5 ± 0.3 3.7 ± 0.2 3.4 ± 0.4 6.1 ± 0.4
K562 5.7 ± 0.3 4.8 ± 0.4 8.1 ± 0.6 3.7 ± 0.3 6.8 ± 0.5 4.6 ± 0.4 4.1 ± 0.6 3.8 ± 0.3 5.3 ± 0.4
8392 4.3 ± 0.3 3.7 ± 0.4 3.2 ± 0.2 2.9 ± 0.4 4.9 ± 0.3 2.8 ± 0.4 2.4 ± 0.2 2.2 ± 0.4 3.4 ± 0.2
aBA is an established, long-term breast cancer cell line. BB to BK represent breast cancer primary cultures of less than four passages. K562 is a human
erythroleukaemia cell line susceptible to LAK cells, and 8392 is an acute T lymphocytic leukaemia cell line resistant to LAK activity. bKASIFLK overexpression,
as determined by immunohistochemical analysis using a human antibody to KASIFLK. cAll CTL lines were tested for specific cytotoxicity after 4 weeks of
stimulation with specific peptide. dDonor nos 5–8 are identical to the donors in Table 1. eData are expressed as average per cent cytotoxicity and standard
deviation of two independent cytotoxicity assays at an E:T ratio of 40:1.CTL recognize RBP-1 345
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CTL cultures that showed significant cytotoxicity were further
stimulated with peptides and established into CTL lines. RBP-1
peptide KASIFLKTRV, which has a motif for both HLA-A2 and
HLA-A3, was less effective than GLQKASIFLK in CTL genera-
tion. Cytotoxicity against peptide-pulsed BLC was greater than
20% for CTL generated from ten of 15 HLA-A2 donors but zero of
ten HLA-A3 donors (data not shown). This suggests that KASI-
FLKTRV is presented primarily in the context of HLA-A2. The
nonamer KASIFLKTR has a motif for HLA-A3 but showed only
weak activity for eliciting peptide-specific CTL; only one CTL
line (from an HLA-A3 donor) demonstrated cytotoxicity greater
than 10%. Twelve representative CTL lines against the three
peptides were consecutively generated from 12 different patients
(Table 1).
The HLA restriction of CTL was then assessed using one estab-
lished breast cancer cell line and ten breast cancer primary cell
lines as targets. Five GLQKASIFLK-specific and four KASI-
FLKTRV-specific CTL lines, all derived from HLA-A2 or HLA-
A3 PBMC, were tested for their cytotoxicity against seven
HLA-A2 and/or HLA-A3 breast cancer cell lines, four HLA-A2–,
A3– breast cancer cell lines, K562 cell line (susceptible to LAK
cells) and 8392 cell line (not susceptible to LAK cells). As shown
in Table 2, the results further supported HLA-A2 and HLA-A3
restricted recognition of GLQKASIFLK and KASIFLKTRV,
although HLA-A3 restricted recognition of the latter peptide was
at a very low level. No significant lysis of breast cancer cell lines
occurred when PBMC were cultured for 4 weeks without peptide
or from HLA-A2–, A3– PBMC stimulated with peptide (data not
shown). The specific lysis of HLA-A2, A3 breast cancer cells by
peptide-specific CTL was inhibited by mAb against HLA-A2,
HLA-A3 or anti-HLA class I, but not by mAb against HLA-DQ or
HLA-DR (Figure 1).
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Figure 1 Inhibition of cytotoxicity of GLQKASIFLK-specific CTL lines by anti-HLA mAb. PBMC from donor numbers 18 (HLA-A2, A2), 19 (HLA-A2, A3) and 20
(HLA-A3, A3) were stimulated with GLQKASIFLK for 16 weeks. Cytotoxicity against allogeneic HLA-A2, A3 breast cancer cell line JWCI-BA (A) and autologous
BLC (B) was assessed at an E:T ratio of 40:1. Each anti-HLA mAb was used at a final concentration of 10 mg ml–1. Cytotoxicity is shown as percent specific
cytotoxicity. Background cytolysis of breast cancer cells expressing other HLA types and nonpulsed BLC was < 2.5%346 T Takahashi et al
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Kinetics of CTL maturation
Figure 2 shows the maturation pattern of representative CTL lines
established by stimulation with each of the three RBP-1 peptides.
Although a higher cytotoxicity was observed in cell lines stimu-
lated with GLQKASIFLK than in cell lines stimulated with KASI-
FLKTRV, the pattern of stimulation was similar. After 4 weeks,
cytotoxicity against breast cancer cells and peptide-pulsed BLC
reached a plateau. The number of cells and specificity of the cell
lines at week 4 decreased when peptide stimulation was inter-
rupted, whereas CTL lines at week 16 were quite stable for both
cell growth and specificity. The phenotyping of CTL lines against
GLQKASIFLK or KASIFLKTRV at wk 16 revealed that these
cells were predominantly CD3+, CD8+, CD4–.
CTL lines stimulated for 16 wk with GLQKASIFLK and KASI-
FLKTRV were tested against autologous BLC pulsed with
0.01–100 mM of the corresponding peptide at an E:T ratio of 40:1
(Figure 3). Cytotoxicity increased in a dose-dependent manner
until peptide concentration reached 1 mM.
Assessment of cross-reactivity among three peptide-
specific CTL
PBMC from an HLA-A2, A3 donor were stimulated for 16 weeks
with each of the three RBP-1 peptides. The cytotoxic activity of
the three ensuing CTL lines was assessed using an autologous
BLC cell line pulsed with each peptide. As shown in Figure 4,
GLQKASIFLK-specific and KASIFLKTRV-specific CTL lines
had 51.2% and 38.1% specific cytotoxicity, respectively, against
BLC pulsed with the respective stimulating peptide, but did
not show significant cytotoxicity against BLC pulsed with the
non-stimulating peptides. KASIFLKTR-specific CTL showed
minimum cytotoxicity against KASIFLKTR-pulsed BLC (13.7%)
and against the HLA-A2, A3 breast cancer cells (15.4%).
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Figure 2 Cytotoxicity of two representative peptide-stimulated CTL lines.
PBMC from donor number 19 (HLA-A2, A3) were repetitively stimulated with
GLQKASIFLK or KASIFLKTRV, and their toxicity against GLQKASIFLK-
pulsed (s) and KASIFLKTRV-pulsed (s s) autologous BLC and against HLA-
A2, A3 breast cancer cell line JWCI-BA (l, l l) was assessed at an E:T ratio
of 40:1. Cytotoxicity against non-pulsed BLC was < 4.0% and subtracted
from each peptide-pulsed BLC cytotoxicity
Figure 3 Peptide dose-dependent lysis of target cells by peptide-specific
CTL. Autologous BLC were pulsed with various concentrations of
GLQKASIFLK (l l) or KASIFLKTRV (s s). Cytotoxicity assays were performed
with respective peptide-specific CTL derived from donor number 21 (HLA-A2,
A3) at an E:T ratio of 40:1. Background cytotoxicity of non-pulsed BLC was
< 3.0%
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Table 3 Cytotoxicity of peptide-specific CTL lines against normal cells and a non-breast cancer cell line
Target cell linesa CTL lines against GLQKASIFLKb CTL lines against KASIFLKTRV
Donor number: 5 6 10 5 6 17
HLA-A: 2, 2 2, 3 3, 68 2, 2 2, 3 3, 29
JWCI-BA breast cancer
(HLA-A2, A3) 72.4 ± 1.8c 80.7 ± 1.7 46.3 ± 1.5 22.8 ± 1.3 38.3 ± 1.1 7.5 ± 0.6
Fibroblast 1 5.7 ± 0.4 6.2 ± 0.3 6.9 ± 0.4 3.7 ± 0.2 4.4 ± 0.4 2.2 ± 0.3
(HLA-A1, A2)
Fibroblast 2 6.1 ± 0.4 7.3 ± 0.4 5.4 ± 0.3 3.2 ± 0.3 3.7 ± 0.1 3.4 ± 0.2
(HLA-A2, A3)
Fibroblast 3 4.60 ± 0.3 5.6 ± 0.5 2.8 ± 0.1 2.9 ± 0.2 5.5 ± 0.3 2.9 ± 0.2
(HLA-A2, A3)
Epidermal cell 2.6 ± 0.2 2.9 ± 0.3 2.0 ± 0.3 2.6 ± 0.3 1.7 ± 0.3 0.0 ± 0.2
(HLA-A2, A3)
JWCI-MA melanoma 1.9 ± 0.2 2.2 ± 0.2 2.5 ± 0.3 2.9 ± 0.1 3.3 ± 0.3 3.2 ± 0.4
(HLA-A2, A3)
aAllogeneic cell lines of breast cancer, fibroblast, epidermal cell and melanoma had either HLA-A2 or HLA-A3 phenotype. JWCI-BA breast cancer cell line
expresses the KASIFLK antigen. JWCI-MA melanoma cell line and normal cell lines were negative for this antigen. bAll CTL lines were tested after 16 weeks of
stimulation with peptide. Donor numbers correspond to those shown in Table 1. cData are expressed as average per cent cytotoxicity and standard deviation of
three independent cytotoxicity assays at an E:T ratio of 40:1.CTL recognize RBP-1 347
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Peptide-specific CTL activity against normal cells and
melanoma cells
Autologous or allogeneic HLA-A2 or HLA-A3 matched normal
cells (fibroblasts, epidermal cells and PBMC) and a melanoma cell
line (HLA-A2, A3) were not recognized by GLQKASIFLK-
specific or KASIFLKTRV-specific CTL (Table 3). Furthermore,
while the cytotoxicity of both CTL lines was almost completely
inhibited by cold target breast cancer cells at a cold:hot target cell
ratio of 20:1, cytotoxicity was not affected by K562 cells, autolo-
gous normal fibroblasts or HLA-A2, A3 melanoma cells used as
cold targets, even at the ratio of 80:1 (Figure 5).
DISCUSSION
In this study we analysed CTL activity against specific peptide
sequences of RBP-1. Previously, we demonstrated that an RBP-1
peptide sequence, KASIFLK, is recognized by human antibodies.
KASIFLK peptide was detected by antibody staining in 12 of 15
(80%) breast cancer specimens, but not in 50 normal tissues (Cao et
al, 1999). In the present study we demonstrate that the heptameric
peptide KASIFLK is recognized by CTL. The inclusion of adjacent
amino acids on the NH2 or COOH terminal of KASIFLK provided
the necessary length and HLA-A anchor motifs for HLA-restricted
T-cell recognition. RBP-1 peptides GLQKASIFLK and KASI-
FLKTRV, both of which contain KASIFLK, stimulated peptide-
specific CTL that recognized respective BLC peptide-pulsed target
cells and breast cancer cell lines.
Presence of the peptide binding motifs does not always predict
HLA-restricted CTL recognition. The peptide KASIFLKTR that
contains HLA-A3 motifs, A at position 2 and R at position 9, did
not induce an effective CTL response (Table 1). This may be
explained by weak antigenicity and/or weak binding of the peptide
to the HLA molecule. An effective peptide sequence for CTL
induction depends on multiple factors. In our system, we can
narrow the selection criteria by using a CTL peptide sequence
built around an antigenic epitope recognized by a human antibody.
The dual effector arms recognizing tumour-associated antigen
peptides do not appear rare (Morioka et al, 1994; Takahashi et al,
1997a, 1997b), and such peptides may represent potential antigens
for active specific immunotherapy.
Immunohistochemical analysis has shown that the specific
antibody recognizing the RBP-1 heptamer peptide sequence
KASIFLK binds predominantly to breast cancer tissues and breast
cancer cell lines (Cao et al, 1999). Although normal cells as well
as other types of cancer cells express RBP-1 mRNA, the antibody
failed to detect the epitope in these cells. We initially attributed
this to the level of expression of the specific peptide sequence
and/or to conformational or post-translational changes of the
protein in breast cancer cells. Future studies will determine the
RBP-1 protein expression levels and the post-translational modifi-
cations in normal and breast cancer cells. However, we have not
excluded the possibility that other proteins expressing KASIFLK
or cross-reactive peptides are responsible for the antibody staining
of the proteins and/or CTL recognition of the peptides.
The overexpression of the RBP-1 peptide or cross-reactive
peptides in breast cancer cells may play a major role in the CTL
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Figure 4 Cross-reactivity of three peptide-specific CTL lines. PBMC from
donor number 21 (HLA-A2, A3) were stimulated with each peptide for 16
weeks and tested for their cytotoxicity against autologous BLC pulsed with
GLQKASIFLK (n n), KASIFLKTRV ( ), KASIFLKTR ( ), and JWCI-BA (n).
Peptides were used at a final concentration of 10 mg ml–1. Specific
cytotoxicity is the mean of three independent assays performed at an E:T
ratio of 40:1.
Figure 5 Cold target inhibition of GLQKASIFLK-specific HLA-A2, A3 CTL
against allogeneic HLA-A2, A3 breast cancer cell line JWCI-BA (A) and
autologous GLQKASIFLK-pulsed BLC (B). The CTL line was derived from
donor number 19 (HLA-A2, A3). Autologous PBMC (l l), HLA-A2, A3
melanoma cells (s s), autologous fibroblasts from normal dermal tissues (n n),
K562 cells (s), and JWCI-BA breast cancer cell line (l) were used as cold
targets. Cytotoxicity assays were performed at an E:T ratio of 40:1. Non-
labelled cold targets were added at the indicated ratios to the hot targetsantigenicity of breast cancer cells. The human antibody detects the
core peptide antigen, KASIFLK, predominantly in the cytoplasm
of breast cancer cells. Antigen presentation with HLA class I
molecules requires cytosolic processing and transportation
(Germain, 1994; Heemels and Pleogh, 1995). Therefore, CTL
recognition of the peptides in breast cancer cells may be related to
intracellular antigen processing that influences HLA presentation
on the cell surface (Nijman et al, 1994).
We observed that RBP-1 peptide-specific CTL could be gener-
ated relatively easily by in vitro stimulation from HLA-A2 and
HLA-A3 healthy donor PBL. This suggests that the peptide is
quite antigenic. However, CTL killing was observed only against
individual breast cancer cells, not against normal cells. A similar
observation has been made for the tumour-associated antigens
MAGE-1 and MAGE-3. MAGE-1 and MAGE-3 specific CTL can
be generated from normal healthy donors as well as from the PBL
of cancer patients; these CTL recognize tumour cells expressing
moderate levels of the respective MAGE antigen (Traversari et al,
1992; Boon et al, 1994; Celis et al, 1994b). These observations
indicate that the antigenic peptide sequence might be recognized
only on tumour cells that overexpress the peptide.
RBP-1 can promote tumour growth by inhibiting the function of
pRB. RBP-1 binds pRB at the binding motif (LXCXE) (Fattaey et
al, 1993). Overexpression of RBP-1, as occurs in breast cancer,
may promote active proliferation of tumour cells. CTL recognition
of tumour cells expressing the RBP-1 peptide antigen would be
important in developing active specific immunotherapies for
prophylactic and therapeutic control of breast cancer. HLA-A2
and HLA-A3 molecules are found in high frequency in the general
population and therefore offer a considerable advantage over a
single HLA-A or HLA-B restricted peptide sequence (Hoon et al,
1998). Recently, several other tumour-associated proteins that are
related to cell growth and cell cycle regulation, such as p53,
HER2/NEU2 and p21 (RAS), have been shown to be antigenic
(Nijman et al, 1994; Peace et al, 1994; Peoples et al, 1994; Gnjatic
et al, 1995; Van Elsas et al, 1995). In future studies we will assess
the in vivo immunogenicity of RBP-1 peptides by studying PBMC
from breast cancer patients.
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